- recruitingPHASE2
Study of Olutasidenib and Temozolomide in HGG
This study is for young people aged 12-39 with a type of brain tumour called high-grade glioma (HGG) that has a specific IDH1 gene change. It tests if a new drug, olutasidenib, combined with standard treatment, can help patients live longer after radiotherapy.
United States · Australia · Canada - recruitingPHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.
United States · Australia · Canada - active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
United States · Brazil · Canada - recruiting
Targeted Pediatric High-Grade Glioma Therapy
This study aims to understand childhood brain tumours better by looking at their genes. For children, teenagers, and young adults with newly diagnosed high-grade gliomas, including DIPG, doctors will check their tumour's genetic makeup to see if they might be suitable for specific new treatments in future trials.
United States · Australia · Canada